PRF科技公司宣布,其候选药物PRF-110在一项头对头的临床前研究中,展现出长达72小时的持续镇痛活性,其效果与已获批并上市销售的标杆对照药物表现相当。
这项研究结果突显了PRF-110作为一种长效镇痛方案的潜力,其作用持续时间与当前市场上的标准疗法具有可比性。该发现为后续的临床开发提供了重要的前期数据支持。
PRF科技公司宣布,其候选药物PRF-110在一项头对头的临床前研究中,展现出长达72小时的持续镇痛活性,其效果与已获批并上市销售的标杆对照药物表现相当。
这项研究结果突显了PRF-110作为一种长效镇痛方案的潜力,其作用持续时间与当前市场上的标准疗法具有可比性。该发现为后续的临床开发提供了重要的前期数据支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.